Welcome to our dedicated page for Syra Health SEC filings (Ticker: SYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Syra Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Syra Health's regulatory disclosures and financial reporting.
Syra Health Corp (SYRA) has filed a Form S-1 registering for resale up to 3,171,100 shares of Class A common stock issuable upon exercise of its Series B warrants. The warrants, issued in a September 2024 registered direct offering, are exercisable at $0.64 per share until September 13, 2029. Syra will not receive proceeds from selling stockholders’ resales but would receive up to about $2.03 million in gross cash proceeds if all such warrants are exercised for cash.
Syra is a healthcare services company focused on behavioral and mental health (including its Syrenity app launched in late 2024), population health analytics, digital health platforms, health education, and healthcare workforce staffing. Revenue was $8.0 million in 2024, $7.2 million in 2025, and $4.7 million for the six months ended June 30, 2026.
The company reported net losses of $3.76 million in 2024 and $0.90 million in 2025, but net income of $0.49 million for the first half of 2026, with an accumulated deficit of $9.23 million and cash of $2.12 million as of June 30, 2026. Its auditor raised substantial doubt about its ability to continue as a going concern, and management expects existing cash and cash from operations will not fund operations for 12 months without additional capital. Syra is an emerging growth and smaller reporting company, trades on the OTCQB, and highlights significant customer concentration and extensive healthcare regulatory and government contracting risks.
Syra Health Corp (SYRA) reported that its COO and CFO, Priya Prasad, received equity awards on August 31, 2026. These include 86,696 Performance Stock Units tied to company financial metrics, 60,687 stock options with a $0.92 exercise price, and 26,009 Restricted Stock Units, all relating to Class A common stock.
Twenty percent of the Performance Stock Units vest each year after the grant date subject to achieving specified company financial metrics. Twenty percent of the options and Restricted Stock Units vest on each of December 31, 2027, 2028, 2029, 2030 and 2031; the options and Performance Stock Units expire on August 31, 2036. No Rule 10b5-1 trading plan is reported.
Syra Health Corp reported that CEO Alexander Gregory R. received a grant of 368,458 Performance Stock Units linked to Class A Common Stock. The units carry a zero exercise price and expire on August 11, 2036. According to the vesting terms, 20% of the Performance Stock Units vest one year after the grant date, with the remaining units vesting upon achievement of specified company financial metrics, tying a substantial portion of this award to the company’s future performance.
Syra Health Corp. reported improved results for the three and six months ended June 30, 2026. Net revenues were $4,667,943 for the six months, up from $3,803,973, driven by growth in population health and healthcare workforce services. For the same period, net income was $491,221 versus a net loss of $535,861 in 2025, reflecting higher gross profit and lower operating expenses. Cash and cash equivalents were $2,123,747 and working capital was $2,551,002 as of June 30, 2026, with net cash provided by operating activities of $643,183.
Despite these gains, management states that there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional capital, citing early-stage operations and limited visibility on revenues. The company also highlights significant customer concentration and dependence on government-related contracts. Subsequent to quarter-end, Syra obtained contract extensions with several customers and disclosed an anticipated CMS ACCESS Model partnership that it expects to be a durable revenue source over ten years.
Syra Health Corp. reported a strong second quarter ended June 30, 2026, with revenue of $2.4 million, up 23% from $1.9 million a year earlier. The company achieved net income of $250,242, compared with a net loss of $63,596, and earnings per share improved to $0.02 from a loss of $0.01.
Gross margin expanded to a record 44.5% from 38.7%, and Q2 EBITDA turned positive to $253,200 from a loss of $53,760. For the first six months of 2026, net income was $491,221 and operating cash flow was $643,183. Cash stood at $2.1 million with no long-term debt. The company renewed key public health and workforce contracts, extended an Indiana FSSA agreement through October 2028, and is pursuing CMS ACCESS Model approval it expects to provide long-term revenue, while targeting full-year 2026 profitability.
Syra Health Corp. held its Annual Meeting of Stockholders on July 23, 2026, with 13,664,105 shares of common stock represented, including 350,000 Class B shares carrying 16.5 votes per share, constituting a quorum.
Stockholders elected all five director nominees to serve until the 2027 annual meeting. They also ratified M&K CPAs, PLLC as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes in favor. In addition, stockholders approved an amendment to the Company's 2022 Omnibus Equity Incentive Plan, increasing the number of Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 against.
Syra Health Corp. is asking stockholders to vote at its July 23, 2026 annual meeting on three items: electing five directors, ratifying M&K CPAS, PLLC as independent auditor for 2026, and expanding the 2022 Omnibus Equity Incentive Plan to 4,100,000 Class A shares.
As of May 28, 2026, there were 13,839,169 Class A shares and 350,000 Class B shares outstanding, with Class B carrying 16.5 votes per share. The proxy details board independence, committee structures, and director pay, including cash retainers and stock options. It also outlines executive compensation and new CEO Gregory R. Alexander’s employment terms, including a $251,000 base salary and sizable equity awards tied to time-based vesting, performance goals, and potential change-in-control treatment.
Syra Health Corp. reported a profitable quarter for the three months ended March 31, 2026, with net revenues of $2,273,520, up about 22% from 2025, and net income of $240,979 versus a prior-year loss. Growth was driven by a $557,961 increase in population health revenue, partly offset by lower healthcare workforce revenue.
Gross profit rose to $971,255, lifting gross margin to roughly 43% as operating expenses fell by $282,218. Cash and cash equivalents increased to $2,922,318 and working capital to $2,345,509. However, management states there is still substantial doubt about the company’s ability to continue as a going concern, noting an accumulated deficit of $9,479,547 and the need to raise additional capital. The business remains highly dependent on government-related contracts and faces funding pressure from changes in U.S. federal spending.
Syra Health Corp. reported its first profitable quarter in Q1 2026. Net income was $240,979, compared with a net loss of $(472,265) a year earlier. Revenue grew 22% to $2.27 million, driven by population health solutions, which rose 46% to $1.8 million.
Gross margin expanded to 42.7% from 31.7% as the company shifted toward higher-margin offerings and improved operating leverage. Operating expenses declined across salaries, professional services, SG&A, and R&D, supporting adjusted EBITDA of $244,495 versus a loss in 2025. Cash and cash equivalents increased to $2.9 million with strong operating cash flow.